In English | En español
Questions About Cancer? 1-800-4-CANCER

Coordinating Center for Clinical Trials

Page Options

  • Print This Page
  • Email This Document

Funded Studies

To date, 34 studies have been funded as part of the BIQSFP program:

Type of StudyFY ApprovedIntegral/ IntegratedCoop Group/ CCOP Study NumberPhaseConcept TitleCancer Site
Biomarker2014IntegralAlliance A071102II-IIIRandomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter HypermethylationGlioblastoma
Biomarker2014IntegralCOG AALL1231IIIA Phase 3 Randomized Trial Investigating Bortezomib (PS-341, Velcade) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LL)Lymphoma
Biomarker2013IntegratedECOG 1412IIRandomized Phase II Open Label Study of RCHOP with and without Lenalidomide in Newly Diagnosed Diffuse Large B Cell Lymphoma   (DLBCL)Lymphoma
Biomarker2013Integral & IntegratedCOG AALL1331IIIRisk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 100135, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Childhood Leukemia
Biomarker2013IntegralALCHEMIST (A151216)II-IIIAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)NSCLC
Biomarker2013Integral & IntegratedSWOG 1314IIA Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN)-Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerBladder
Biomarker2013IntegralRTOG 1305II-IIIRandomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus
(EBV) Deoxyribonucleic Acid (DNA)
Biomarker2013IntegratedCOG ANBL1232IIIUtilizing Response-and Biology-Based Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaChildhood Neuroblastoma
Biomarker2013IntegratedSWOG 1300IIA Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients who have Progressed Systemically after Previous Clinical Benefit from Crizotinib MonotherapyLung
Imaging2013IntegratedRTOG 1221IIRandomized Phase II Trial of Transoral Endoscopic Head and Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx CancerOropharynx
Biomarker2013IntegralCabozantinib Studies (ECOG, GOG, Alliance)IIMeasurement of MET/IHC Across Patients with Ovarian, RCC, NSCLC, and Ocular Melanoma CancersOvarian, RCC, Lung, OM
Biomarker2013IntegratedRTOG 1201IIA SMAD4-driven Phase II Randomized Trial of High Versus Standard Intensity Local or Systemic Therapy for Unresectable Pancreatic CancerPancreas
Biomarker2012Integral & IntegratedECOG 1910IIIA Phase III Randomized Trial of Blinatumomab for Newly Diagnosed bcr-abl Negative B Acute Lymphoblastic Leukemia in AdultsAdult ALL
Imaging2012IntegratedAlliance A031201IIIPhase III Trial of MDV3100 vs. MDV3100 and Abiraterone and Prednisone for Castration Resistant Metastatic Prostate CancerProstate
Biomarker2012IntegralRTOG 1216II-IIIRandomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and NeckHead & Neck
Biomarker2012IntegralCOG ASCT1221IIRandomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)JMML
Biomarker2012IntegralSWOG S1201IIA Randomized Phase II Pilot Study Prospectively Assigning Treatment for Patients Based on ERCC1 for Advanced/Metastatic Gastric Cancer or Gastroesophageal (GE) Junction CancerGastric/GE junction
Biomarker2011IntegralACOSOG Z11103II-IIIAlternate Approaches for Clinical Stage II & III Estrogen Receptor + Breast Cancer Neoadjuvant Treatment (ALTernate) StudyBreast
Biomarker + Imaging2011IntegralCALGB 80803IIA Randomized, Phase 2 Trial of PET Scan-Directed Combined Modality Therapy in Esophageal CancerEsophageal
Biomarker2011IntegralRTOG 1016II-IIIPhase II-III Trial of Moderate De-Escalation of Chemotherapy and Radiation in Favorable Risk, Locally Advanced, HPV-Associated Oropharynx CancerOropharynx
Biomarker2011IntegratedCOG ACCL0933QOLProspective Evaluation of Galactomannan and (1→3)-β-D-glucan Assays as Diagnostic Tools for Invasive Fungal Infection in Children with Acute yeloid Leukemia Receiving Fungal ProphylaxisPeds ACL
Biomarker2011IntegratedCOG ACCL0934QOLProspective Surveillance of Resistance in Colonizing Bacteria from Stool or Perirectal Swab Cultures and in Bacterial Isolates from Sterile Site Cultures in Pediatric Patients Receiving Levofloxacin for Acute LeukemiaPeds ACL
Biomarker2011IntegratedCOG AALL 1131QOLIncidence & Natural History of Osteonecrosis (ON) + Longitudinal, Computerized Assessment of Neurocognitive Functioning in Children with High-Risk Acute Lymphoblastic Leukemia (PARENT STUDY: Treatment of Newly Diagnosed High-Risk B-precursor Acute Lymphoblastic Leukemia)Peds ALL
Biomarker2010Integral & IntegratedSWOG 0819IIIA Randomized , Phase 3 Study Comparing Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)NSCLC
Biomarker2010IntegralSWOG S1007IIIA Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and HER2-negative Breast Cancer according to Recurrence Score (RS)Breast
QOL2010IntegratedCOG AALL 0932QOLLongitudinal assessment of vincristine-associated peripheral neuropathyPeds ALL
Biomarker2010Integral & IntegratedCOG AAML 1031IIIA Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Lestaurtinib for patients with FLT3 ITDPeds AML
Imaging2010IntegratedRTOG 0825IIIPhase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed GlioblastomaGlioblastoma
Biomarker2010IntegralRTOG 1010IIIA Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing Esophageal AdenocarcinomaEsophageal
Biomarker2010IntegralNCCTG N0577IIIPhase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic GliomaGlioma
Biomarker2009Integral & IntegratedCALGB 30801IIIA Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung CancerLung
Biomarker2008IntegralCOG AAML0531IIIA Phase III Randomized Trial of Gemtuzumab Ozogamicin Mylotarg® Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young AdultsPediatric AML
QOL2010IntegratedNSABP-MA 32FIIIBiobehavioral Mechanisms of Fatigue in Patients Treated on MA 32: A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (A Phase III Clinical Trial Comparing Adjuvant Sunitinib Malate to Placebo in Women with Residual Invasive Breast Cancer Following Neoadjuvant Chemotherapy)Breast
QOL2008IntegratedCOG UC0604IIIA Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxed/Carboplatin Chemotherapy in Patients with High Risk Early Stage Endometrial CarcinomaUterine